Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke

Aging is a risk factor for major central nervous system (CNS) disorders. More specifically, aging can be inked to neurodegenerative diseases (NDs) because of its deteriorating impact on neurovascular unit (NVU). Metformin, a first line FDA-approved anti-diabetic drug, has gained increasing interest...

Full description

Saved in:
Bibliographic Details
Published in:Life sciences (1973) 2021-06, Vol.274, p.119343-119343, Article 119343
Main Authors: Sharma, Sejal, Nozohouri, Saeideh, Vaidya, Bhuvaneshwar, Abbruscato, Thomas
Format: Article
Language:English
Subjects:
Aging
Aging - drug effects
Aging - pathology
Animals
Anti- aging
Brain Ischemia - drug therapy
Brain Ischemia - pathology
Central nervous system
Diabetes
Diabetes mellitus
Disabilities
Drug Repositioning - methods
Electronic cigarette vaping
Health risks
Humans
Hypoglycemic Agents - therapeutic use
Ischemia
Ischemic stroke
Metformin
Metformin - therapeutic use
Neurodegenerative diseases
Neurodegenerative Diseases - drug therapy
Neurodegenerative Diseases - pathology
Risk analysis
Risk factors
Stroke
Stroke - drug therapy
Stroke - pathology
Tobacco smoking
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aging is a risk factor for major central nervous system (CNS) disorders. More specifically, aging can be inked to neurodegenerative diseases (NDs) because of its deteriorating impact on neurovascular unit (NVU). Metformin, a first line FDA-approved anti-diabetic drug, has gained increasing interest among researchers for its role in improving aging-related neurodegenerative disorders. Additionally, numerous studies have illustrated metformin's role in ischemic stroke, a cerebrovascular disorder in which the NVU becomes dysfunctional which can lead to permanent life-threatening disabilities. Considering metformin's beneficial preclinical actions on various disorders, and the drug's role in alleviating severity of these conditions through involvement in commonly characterized cellular pathways, we discuss the potential of metformin as a suitable drug candidate for repurposing in CNS disorders. [Display omitted] •Aging-related CNS disorders have complex pathophysiology with few or no treatments.•Studies show that, metformin, an anti-diabetic drug, has neuroprotective action.•Consideration of dose, duration and timing of treatment is important for metformin use.•Metformin has the cerebroprotective potential for ischemic stroke.•Metformin is a suitable candidate for repurposing in aging-related CNS disorders.
ISSN:0024-3205
1879-0631
DOI:10.1016/j.lfs.2021.119343